A novel TRIM family member, TRIM59 gene was characterized to be up-regulated in SV40Tag oncogene directed transgenic and knock-out mouse prostate cancer models. As a signaling pathway effector, we identified two phosphorylated forms of TRIM59 (p53 and p55), and characterized them using purified TRIM59 proteins from mouse prostate cancer models at different stages with wild-type mice and NIH3T3 cells as controls. p53/p55-TRIM59 proteins possibly represent Ser/Thr and Tyr phosphorylation modifications, respectively. Quantitative measurements by ELISA demonstrated that the p-Ser/Thr TRIM59 correlated with tumorigenesis, while the p-Tyr-TRIM59 protein correlated with advanced CaP. The function of TRIM59 was elucidated using shRNA-mediated knockdown of the gene in human CaP cells, which caused S phase cell cycle arrest and cell growth retardation. A "hit-and-run" effect of TRIM59 shRNA knockdown was observed 24 h post-transfection. Differential cDNA microarrray analysis was performed, which demonstrated that the initial and rapid knockdown occurred early in the Ras signaling pathway. To confirm the proto-oncogenic function of TRIM59 in the Ras signaling pathway, we generated a transgenic mouse model using a prostate tissue-specific gene (PSP94) to direct the up-regulation of the TRIM59 gene. Restricted TRIM59 gene expression in the prostate revealed the full potential for inducing tumorigenesis, similar to the expression of SV40 Tag, and coincided with the up-regulation of genes specific to the Ras signaling pathway and bridging genes for SV40Tag-mediated oncogenesis. The finding of a possible novel oncogene in animal models will implicate a novel strategy for diagnosis, prognosis and therapy of cancer.
Introduction
The TRIM (TRIpartite Motif) family is an evolutionarily conserved gene family implicated in a number of critical processes including immunity (1) (2) (3) , antivirus (4) (5) (6) (7) (8) , proliferation (6, 9) , transcriptional regulation (6, 10) , , neuro-development (11, 12) , cell differentiation (12) and cancer (13) (reviewed in (1, 5, 14, 15) ). However, the function of most TRIM family members is poorly understood and was surmised only based on computational analysis from their RBCC (RING finger, B-box, Coiled-Coil) sequences. RING (Really Interesting New Gene) domain genes are frequently involved in proteolysis acting as E3 ubiquitin ligases and the ubiquitin-proteasome system in the regulation of numerous cellular processes including cell cycle regulatory proteins, transcription factors, and signal transducers (6, 15) . Antiviral activity associated with the RING -finger E3s has been reported in several members of the TRIM gene family, including the HIV restriction factor TRIM5α variant (2, 8) and the disease-associated proteins. B-boxes (1) (2) are domains that bind one Zn 2+ , although their function is unknown.
Recent reports demonstrate TRIM members function in microRNA processing (14) . A large class of TRIM-NHL proteins were characterized with functions as a cofactor for the microRNAinduced silencing complex (miRISC) (14, 16) . TRIM32 activates microRNAs, targets and ubiquitinylates c-Myc for proteasome-mediated degradation so prevents self-renewal in mouse neural progenitors (12) . An ataxia-telangiectasia group D complementing gene (ATDC) was reported in most invasive pancreatic cancers up-regulated in the Wnt/β-catenin signaling pathway (13) .
Since cancer of the prostate (CaP) does not occur naturally in rodents, autochthonous genetically engineered mice (GEM)-CaP models has been generated (for review, see (17) ).
Currently, the most widely used GEM-CaP models all utilize SV40Tag {344, 456} . We have established two GEM-CaP models in which the PSP94 promoter drives the expression of T/tag to the prostate (18) (19) (20) (21) : the PSP-TGMAP (PSP94 gene-directed TransGenic Mouse Adenocarcinoma Prostate) model (18, 21, 22) and the PSP-KIMAP (Knock-In Mouse Adenocarcinoma Prostate) model (19, 20) . We performed a series of cDNA microarray analyses to study up-regulated gene profiles (23) . One of these up-regulated genes, TRIM59 (NM_025863, 2858 bp) with unknown function in Tag -induced transgenic mouse models, was chosen for further analysis.
Materials and Methods (More details see Supplemental M&M)
PSP94 gene directed TRIM59, TGMAP (18) (19) (20) and KIMAP (19, 20) GEM-CaP models, histology and pathology: A 3.84 kb promoter/enhancer region of the PSP94 gene were used in all transgenic mouse models for targeted up-regulation in the mouse prostate. Protocols for mouse micro-dissection, anatomical, pathological and histological grading were performed as previously reported (18-20, 22, 24) . Histo-pathological classifications were performed according to the standard (18) (19) (20) and were scored blindly by pathologist (MM) and at least two authors independently. All animal experiments were conducted according to the approved University Council of Animal Care (UCAC).
cDNA microarray (GeneChip, Affymetrix) analysis: Total cellular RNA were extracted using a RNeasy Mini Kit (Qiagen, Valencia, CA) as previously reported (23) (20) . All chip experiments were performed at the London Regional Genomics Centre. All GeneChips were from Affymetrix: MG_U74Av2, MOE430A or MOE 430 2.0 (23) for mouse and HGU133 Plus 2 for human cell line. Gene expression levels were analyzed using standard softwares.
Semi-quantitative, real-time RT-PCR and Northern blotting were performed according to reported procedures (20, 23, 25) . Real time PCR was conducted according to the Invitrogen kit (SYBR GreenET qPCR SuperMix Universal) by the ABI 7900 Real Time PCR System and tested by 3 dilutions of the template cDNA. All oligo-primers used were listed in Supplemental Expression of recombinant GST-mouse TRIM59 fusion protein, generating of mouse TRIM59 antibodies: A full length cDNA clone of mouse TRIM59 (2858 bp) was purchased (Invitrogen MGC IRAV 4017983) and used for cloning into pGEX2T vector (GE-Amersham).
All purification procedures of GST-fusion proteins were following the manufacturer's manuals. Approximately 1.5 mg of purified GST-TRIM59 proteins were immuned to rabbit.
Immunohistochemistry (IHC):
Standard ABC (Avidin Biotin Complex) protocol was performed as previously reported (21, 22, 24) . All human tumor biopsy samples were analyzed histologically as approved by the University ethic committee.
Cell culture and
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P labeling in cultured cells: Mouse fibroblast cell line NIH 3T3, human prostate cancer cell lines DU145, PC3, LNCaP, and human cell line HEK293, were purchased directly from ATCC and maintained in DMEM (Invitrogen/Gibco) with 10 % fetal bovine serum. Numbers of passages of cell culture were minimized by fresh retrieval from original liquid nitrogen stock (less than 6 months of cultured cells) for the new project.
P labeling of total cellular phosph-proteins in cultures cells was conducted as per (25) . Labeled proteins were immunoprecipitated (IP) with TRIM59 antibodies according to IP procedures.
Detection of phosphoprotein by IMAC (Immobilized Metal Affinity Chromatography)
column: Tissue lysates were first titrated by BioRad protein assay, and all experimental procedures were performed according to (23) and the manufacturer's instructions (from PhosphoProtein kit, Qiagen, Montreal Que and Phosphoprotein Enrichment kit, Clontech, CA).
Samples were taken from every separation procedure (named "before", "pass", "wash", eluate "E1", "E2"…). All purified proteins were concentrated by centrifugal ultra-filtration (Ultrfree- ELISA quantification of mouse TRIM59 proteins was followed as previously reported (21) 
Results
Characterization of the novel TRIM59 gene related to SV40 Tag-induced tumorigenesis in
GEM-CaP models
The GeneChip analysis showed that the TRIM59 gene (NM_025863) was up-regulated by 16 .84 and 24.07-fold at 20 and 60 wks (23) , respectively in the KIMAP mice, compared to the wild-type (WT) control. These age groups exhibit histological changes that are representatives of tumorigenesis, including prostatic intraepithelial neoplasia (PIN), well-differentiated (WD) CaP, and moderately differentiated (MD) CaP. In contrast, TRIM59 was down-regulated by 0.6-fold in large, poorly differentiated (PDCaP) tumors in the TGMAP model with androgen independent (AI) and neuroendocrine (NE) carcinoma features within 4 to 8 months of age, which was similar to that induced by SV40 Tag expression (26) , (23) . Fig. 1A shows bioinformatics data for the TRIM59 gene, including the structure, cDNA and protein open reading frame (ORF), and hypothetical RBCC domains. Semi-quantitative RT-PCR (20, 23) confirmed that TRIM59 mRNA were higher in KIMAP tumors than in the WT controls at 20 and 60 wks of age as well as mouse fibroblast NIH3T3 cells after normalization against GAPDH (Fig. 1B) P-dCTP-labeled 250 bp RT-PCR products showed a 2.5 kb mRNA band, which migrated at the predicted size (Fig. 1C) .
To characterize the protein product, we generated two polyclonal antibodies (Fig. 1A) .
The first antibody, GST-TRIM59#71, was raised against recombinant TRIM59 that contained an N-terminal fragment (163 aa) covering several hypothetical RBCC domains. The second antibody, GST-TRIM59#72, was raised against recombinant TRIM59 that contained the Cterminal fragment (126 aa) that was composed predominantly of TRIM59-specific epitope sequences. The TRIM59#72 antibody detected a unique or a major band of 53 kDa that was close to the predicted size of 44.77 kDa (403 aa) in western blots probing lysates from cultured cells ( Fig. 2A) and GEM-CaP tissues (Fig. 2D ). The N-terminal TRIM59#71 antibody recognized multiple bands, however the same unique band was detected when the antibody was used to probe proteins purified from the TRIM59#72 affinity column (see Supplemental Fig. s-1 ).
IHC staining of GEM-CaP tissues with the TRIM59#72 antibody showed positive staining of TRIM59 in 5 main grades of hyperplasia, including PIN, WD, MD, and PD CaP, and negative staining in the WT tissue ( Fig. 1D, E) . We scored by foci the extent of TRIM59#72 IHC staining in GEM-CaP mice (n=20). Graph ( Fig. 1E ) showed that nuclear staining in the cell proliferative area, i.e. PIN and in all cancer foci was significantly higher (P<0.01) than in the cytoplasm. However, there was no difference in cytoplasmic staining with cancer foci (Fig. 1F ).
The IHC staining intensity for TRIM59 was lower in late stage tumors (PDCaP). TRIM59 protein was predominantly expressed in the cytoplasm of cells. (Fig. 1D , red arrows). As a control, IHC of SV40 Tag showed that the protein localized exclusively in the nucleus (Fig. 1D , black arrows).
Characterization of phospho-TRIM59 protein by phosphor-protein affinity IMAC
Since most of the downstream effectors of SV40Tag are phosphorylated proteins located in the nucleus, including pRB and p53, we first characterized the state of phosphorylation (p-) of TRIM59 in order to demonstrate that TRIM59 was possibly a downstream effector of SV40 Tag.
Using IMAC enrichments, we noticed that the intensity of the p-53kDa band did not change after the lysates were passed through IMAC. Densitometry measurements of the western blots revealed that only approximately 1/250th of the total cellular protein contained phosphorylated TRIM59. Two bands that had a molecular weight of 53kDa and 55kDa reacted with the TRIM59#72 antibody and were designated as p-53 and p-55-TRIM59, respectively ( Fig. 2A) . We repeatedly observed this result in most of the IMAC experiments, as shown by the elutions from the Qiagen and Clontech purification kits (Fig. 2B) . Addition of 0.5x, 1x, and 2x PBS as a competitor to the cell lysates that were loaded onto the IMAC columns blocked the binding of TRIM59-p53 and -p55 to the column ( Fig. 2A) . Whereas other three phospho-proteins immunoreactive to TRIM59#72 antibody which may be due to overloading of proteins from concentrated IMAC elutions, were less sensitive to the competition (data not shown). We further confirmed this result by adding GST-TRIM59#72 as a competing immunogen in the western blot experiments (data not shown). The 32 P labeling of total cellular phospho-proteins in cultured NIH3T3 cells showed that a p-TRIM59 band was present after immunoprecipitation using the TRIM59#72 antibody immobilized on an agarose gel matrix (Fig. 2C) .
Two phospho-TRIM59 forms correlate with tumorigenesis and progression in GEM-CaP mice
We applied the same IMAC column enrichment to GEM-tumor tissues (Fig. 2D) obtained from KIMAP mice with PIN or WD (20 wks, n = 12), MD CaP mice (40 wks, n = 11; 60 wks, n = 7), and TGMAP (TG) mice (late stage tumors, n = 5). The p-TRIM59-p53 and -p55 forms were again identified and were similar to those seen in the NIH3T3 cells (Fig. 2D) .
TRIM59-p55 appeared as a weaker band and was found exclusively in large tumors from TGMAP (Fig. 2D) . The semi-quantitative western blots showed that the levels of TRIM59-p53 in the 20 and 40 wk-old KIMAP mice appeared to be higher than those in the 60 wk-old age group, TGMAP mice, and WT mice. More protein was loaded in the WT samples in order to visualize the TRIM59 band, since these samples had lower TRIM59 levels. Normalized tissue lysates and pass through fractions were used as controls, since both β-actin and GAPDH are not phosphorylated proteins (Fig. 2D ).
To further investigate the TRIM59 phosphorylation sites, we purified TRIM59 proteins on an affinity column coupled with the TRIM59#72 antibody. We first tested pooled lysates from large TGMAP tumors (n =12) by western blot and probed the membranes with two different antibodies against phospho-tyrosine (p-Y; Fig. 2E ) and phospho-threonine (p-T, which stands for all p-S/T proteins; Fig. 2H ). As a control, the same blots were re-probed with the TRIM59#72 antibody to identify total TRIM59 protein ( Fig. 2F and 2I ). As shown in Fig. 2E and F TRIM59 (Pi) showed slightly higher mobility in SDS-PAGE than the non-phosphor-form (-Pi).
The p-T-TRIM59 protein had approximately the same mobility as the non-phosphorylated form (Fig. 2H) . Densitometry scanning of the blots shown in 2E vs. 2F and 2H vs. 2I showed that approximately 30% and 70% of the total p-TRIM59 protein were p-Y and p-S/T residues, respectively.
To confirm the specificity of the re-probing test, we used an immobilized p-Y antibody to immunoprecipitate the affinity column purified TRIM59 and confirm the p-Tyr antibody reprobing experiment (Fig. 2G) . Similarly, we also confirmed that less p-T and p-Y residues of p-TRIM59 were detected in the KIMAP mice (20-40 wks of age; n= 15) by performing an immunoprecipitation using TRIM59#72 immobilized antibody (data not shown).
ELISA quantification demonstrates that TRIM59 protein and hyperphosphorylation correlate with SV40 Tag-induced oncogenesis
To quantify the concentration of total TRIM59 protein and the p-forms, we established an ELISA protocol. We utilized TRIM59 protein purified on an affinity column from prostate tumors of 10 mice each from the KIMAP and TGMAP models. WT mice and NIH3T3 cells were used as controls. The elution fractions E1 and E2 of the TRIM59 protein (as shown in Fig. 2E-I) were tested separately, since P-S/T-and p-Y-TRIM59 protein were roughly separated in these first two fractions (Fig. 2J2-3 ). The TRIM59#72 antibody was used to measure the total TRIM59 protein concentration and served as reference for the normalization of all other samples (Fig.   2J7 ).
The ELISA results showed that the TGMAP mice had the highest levels of Y phosphorylation, which was 2-3 times higher than the KIMAP and WT control, and suggested an association with the progression to large, late-stage AI and NE CaP (Fig. 2J9) . Moreover, TGMAP and KIMAP displayed higher levels of total TRIM59 protein, p-Y-, and P-S/Tphosphorylated TRIM59 than WT mice (Fig. 2J7, 8) . Therefore, p-S/T TRIM59 hyperphosphorylation may correlate with SV40 Tag-mediated tumorigenesis. Surprisingly, the NIH3T3 cells displayed a high percentage of p-S/T TRIM59 protein, which may have been due to the high rate of cell proliferation (Fig. 2J8) . 
To investigate TRIM59 function, we performed knockdown experiments of TRIM59 mRNA expression using a mixture of four shRNA plasmids, which targeted the 5' end (sh1) and 3' end (sh2 and sh3) of the human TRIM59 ORF as well as the 3' UTR (sh4). The last shRNA plasmid bound closely to the miR17 target sequence (27) (Fig. 1A) . Transient transfection of the human CaP cells and analysis by FCM revealed a statistically significant (P = 8 x 10 -7
; repeated 20 times) decrease in the percentage of S phase cells for both the DU145 and PC3 cells compared to other phases of the cell cycle (subG1, > G1, G0/G1, S, G2/M, 3N, and 4N) and the control (pSilencer neo-negative, from Ambion kit, Fig. 3A and B) . All five CDC phases were decreased, except sub-G1 phase cells (P>0.05). Stable transfectant clones (n = 7; Fig. 3C, D) also demonstrated cell cycle arrest in the S phase (P = 0.002).
Cell proliferation assessment showed significant growth retardation (50-30% reduction compared to control) in both transient (Fig. 4A ) and stable transfectants (Fig. 4B) . shRNA knockdown of TRIM59 in a slow growing human CaP cell line (LNCaP) caused significant cell death (data not shown). Real-time RT-PCR quantification of three dilutions of cDNA templates showed that TRIM59 mRNA was decreased by 50% 24 h after the transient transfection in DU145 and PC3 cells, and returned to normal levels 48 h after the transfection (Fig. 4C) .
Similar results were observed in all of the DU145 and PC3 stable transfectants (Fig. 4F) . Both pSilencer-neg and pcDNA plasmids were used as negative controls and the experiments were repeated four times.
A "hit-and-run" effect of targeting TRIM59 in the Ras signalling pathway suggests it is an early and rapid signal transmitter
We hypothesized that due to a "hit-and-run" effect, the effects on the original signaltransduction targets of TRIM59 could only be detected at 24 h post-transient knockdown (Tr24), but not at later time points or in the stable transfectants (S), despite that fact that they had the same phenotype. Since TRIM59 function is critical for cell survival, we only observed a rapid and transient, less than a 50% reduction in shRNA-mediated knockdown of TRIM59 expression.
We only detected marginal reductions of TRIM59 protein and hyper-phosphorylation in western blot experiments (data not shown), which may be due to TRIM59 acting as an early and rapid signal transmitter. We performed a differential GeneChip experiment using the S and Tr24 samples. The results of the GeneChip confirmed the "hit-and-run" hypothesis and showed that TRIM59 mRNA had a 16% reduction compared to the S group. Fig. 4E shows two kinds of differential GeneChip analyses. The first analysis was the "Unique Tr24-S grey zone" (n=43), which screened for genes in the Tr24 group that had a unique decrease of 1.5-fold compared to genes in the S group, which only had a ± 10% change (grey zone). The second analysis was the "Unique Tr24-S D" (n = 59), which assessed differences greater than 1.3-fold between the genes of the Unique Tr24 and S groups (either decreased or increased). Both of these two differential screening analyses, which are shown by "Unique Tr24-S (grey zone)" (Fig. 4F2) and "Unique Tr24-S D" function group maps (Fig. 4F3) , exhibited a unique and rapid down-regulation of KRas oncogenes, such as K-Ras and RasSF5. In contrast, only Ras downstream genes (e.g. PI3K/Akt and Rho) were observed in the S group (Fig. 4F1) . Supplemental Fig. s-2 provides the detailed lists and GeneChip heat maps.
TRIM59 has proto-oncogenic activity in a transgenic mouse model test
To test the oncogenic activity of TRIM59 in the Ras/SV40Tag signaling pathways, a transgenic mouse prostate model was developed, which utilized a prostate tissue-specific gene promoter of the PSP94 gene to directly up-regulate mouse TRIM59 gene expression (Fig. 5A ).
Transgenic up-regulation of TRIM59 was confirmed by RT-PCR using primer pairs of FLAG (3' end) and a 300 bp upstream oligonucleotide (Fig. 5B, Supplemental Table s-1) . The GeneChip also confirmed TRIM59 gene up-regulation (2.24-fold). Four F0 breeding lines, which were bred until F3 with 60 male mice, were established. Histopathological analysis was performed on 15 mice that were 100-110 days-old from all four established breeding lines (Fig. 5C, F0-F3 until 12 mo of age). The results of the H&E staining of the prostate samples showed that 3 mice developed WDCaP, which was mostly in the dorsolateral prostate (DLP) and the region that is most sensitive to carcinogenesis in rodents (28) , 6 mice developed low to high grade PIN, and 6 mice were normal. Atrophic glands were often observed (Fig. 5D) . One hundred and ten day-old PSP94-TRIM59 mice also showed invasion (IC) of the surrounding glands and the formation of fused glands (Fig. 5C, WDCaP-IC) . Figure 4C GeneChip analysis was performed using WT mice as references. The TRIM59 gene was upregulated by 2.24-fold in the GeneChip analysis. Out of the genes that were up-regulated by 10-fold, the majority of them (68/201, 50.7%) were previously described tumor markers, which confirmed that the PSP-TRIM59 model was a valid cancer model ( Supplemental Fig s-3) . The high proportion of immune-responsive genes (26/201, 19 .4%) may account for the low tumor incidence and slow growth rate of CaP in PSP94-TRIM59 mice, which is similar to that observed in the KIMAP model (19, 20) .
In PSP94-TRIM59 mice, we also verified that the TRIM59 gene functioned in the Ras signaling pathway. The more intense staining of TRIM59 protein by IHC was predominantly found in the cytoplasm of cells located in the cell proliferative area of PIN and WDCaP foci (Fig.   5C ), whereas only 10% of the cells showed TRIM59 nuclear staining (30/323). It is important to note that the Ras/Braf/MEK/ERK signaling pathways reside either near the cell membrane or in the cytoplasm, which is in contrast to the nuclear location of the SV40Tag/pRB/p53 pathway proteins. However, both pathway families regulate cell division and proliferation (29) .
As shown in Fig. 4F4 , the genes up-regulated by 10-fold and most of the genes upregulated by 2-10-fold were related to the Ras signaling pathway (n=66) For example, Rho factors and G proteins comprised 38.4% (24/66) of the total genes in these groups. Supplemental Fig. s-3 shows the heat maps for the genes in the list. As a control, the same GeneChip analysis performed on PSP94-SV40Tag-directed GEM-CaP models revealed that most of the gene profiling related to abnormality of the CDC checkpoint system and chromosome instability (20, 23) . However, we identified exceptions to these observations, and showed that some genes involved in both the Ras/Braf/MEK/ERK and SV40 Tag/pRB/p53 pathways were up-regulated in the PSP94-TRIM59 mice (Supplemental Table s 
performed on seven Ras-related genes (Rac2, Pla2g2a, Fos, Gpr120, Gpr18, Sgpp2 and Styk1), five SV40 Tag effector genes (Rbbp4, Rbbp8, Trp53bp1, P107, and Ccnb1-rs1), and one NECaP marker gene (Chromogranin, ChgA). Prostate samples were tested from three GEM-CaP models, including hybrids of F1 (KIMAP xPSP94-TRIM59), using the WT mice as controls. Fig.   6 shows that Ras-related genes were up-regulated in PSP94-TRIM59 and had higher expression levels than those in the KIMAP or hybrids of PSP94-TRIM59 x KIMAP mice, with the exception of bridging genes, such as Rac2 and GPRs. All Tag effectors were higher than either PSP94-TRIM59 or the hybrids of PSP94-TRIM59xKIMAP, with the exception of the bridging genes Ccnb, P107, and Rbbps, indicating a dominant effect over Ras-related genes.
Discussion
In this study, a novel TRIM family member, the TRIM59 gene was originally screened for up-regulation and association with the SV40Tag oncogene-mediated tumorigenesis in GEM-CaP models. As with all downstream effctors from Ras and SV40 Tag oncogene families, TRIM59 function target still involved in S-phase and cell proliferation regulation.
However, we found that the initial functional targets of TRIM59 may possibly targeted are actually in the Ras oncogene signal pathway. We hypothesize that a mechanism should exist linking between Ras and SV40Tag/pRB/p53 oncogene signal pathways, one of which is possibly through a new TRIM59 signal-transduction route (diagram shown in Supplemental Fig.   s-4) . The mechanism coordinating between two large oncogene signal pathways is still not clear, which the RING-domain ubiquitinase activities will be involved (15) . We assume that TRIM59- (29) . TRIM59 expression up-regulation, especially the p-Y hyper-phosphorylation increased in the nucleus mostly in MD-PDCaP stage. All other signal pathways with connections with TRIM59 knockdown or up-regulation (e.g. Wnt-β-catenin, BMP-SMAD, IGF etc, shown Fig. 4F, Fig. s-2 and 3) were initially or majorly expressed in the cytoplasm. In a recent report Ras and pRb functionally interact, in spite of their geographical distance, resolving a signaling network involved in cellular senescence and tumor suppression (30) . Finally, GeneChip analyses on the PSP94-TRIM59 up-regulation transgenic mouse test also confirmed that genes related to Ras signal pathway are the most significant up-regulated group.
It is just because TRIM59 as an early signal transmitter that we investigated 289 human cancer cases, and demonstrated TRIM59 up-regulation in the cytoplasm in all 35 tumors types tumors (29) . Further evidences also from the "hit-and-run" effect of TRIM59 gene function, which may implicate TRIM59 as a "rapid" signal transmitter in Ras signal pathway. Probably due to this "rapid" effect, results of our western blotting semi-quantitative test on levels of (DYKDDDDK), an immuno-epitope tag, and followed by SV40 small-t splicing and poly A tail sequences. Genotyping for four breeding lines were determined by two sets of primers (by arrows, Table S-1) by a quick tail PCR procedure (18) (19) (20) . 
